liver transaminase
Analysts Downplay Intellia Adverse Event, but Gene Therapy Safety Remains Under Scrutiny
Intellia Therapeutics; gene therapy; safety event; adverse event; MAGNITUDE trial; liver transaminase; stock decline; ATTR-CM; gene editing; analyst response